Helixgate

Helixgate

Uncategorized

Common Ancestry Limits Protein Sequence Exploration, Computational Study Shows

Published

on

For all the excitement surrounding AlphaFold and the surge of AI‑driven protein design tools, one fact often goes unexamined: nearly every model is trained on databases of known proteins. These databases feel vast, but compared to the astronomical number of sequences that could, in principle, form a functional protein, they represent only a sliver of what’s possible. That raises a fundamental question for the field: how representative is the protein universe we currently know?

A new study published in PNAS and titled “Descent from a common ancestor restricts exploration of protein sequence space,” takes direct aim at that question, using large‑scale protein evolution modeling to probe the limits of protein diversification. The work, led by researchers at the Okinawa Institute of Science and Technology (OIST), the Institute of Science and Technology Austria (ISTA), the University of Vienna, and the Centro de Astrobiología (CAB), suggests that the boundaries of today’s protein diversity were set remarkably early in life’s history.

“Modern AI methods are thought to be revolutionizing protein design,” said Fyodor Kondrashov, PhD, who heads OIST’s Evolutionary and Synthetic Biology Unit, in a press release. “Yet most of these AI design methods are typically trained on databases of known proteins. Without understanding how representative these known proteins are of sequence space, how confident can we be that such methods can generate truly diverse protein designs?”

Protein sequence space for a biological function
An abstract, not-to-scale visual representation of different protein sequence spaces for a particular biological function. A large box represents all possible amino acid sequences (approximately 20L number of combinations, where L is the chain length). A smaller blue patch represents the sequences that create functional proteins, and an even smaller green area shows the sequences that we have historically confirmed to exist. Gold-colored lines show protein evolution pathways, with red paths describing evolutionary lines describing extinct pathways (i.e., those that aren’t thought to be present in modern biodiversity). [Isakova et al.]

To investigate that representativeness, the team began by mathematically describing the region of sequence space occupied by known proteins. They estimated the “dimensionality” of each protein family, a measure of how many independent directions evolution has actually sampled, using correlation‑based analyses of sequence variation. The researchers then simulated protein evolution to test how ancestry, selection, and epistasis shape the diversity of sequences that evolution can reach. The goal was to estimate how many functional sequences should exist for a given protein family and to compare that theoretical diversity with the diversity observed in nature.

What emerged was a striking pattern: the strongest constraint on protein evolution is not selection or epistasis, but ancestry itself. Proteins tend to remain clustered near the sequences of their earliest ancestors, with limited divergence into the broader functional landscape. As the authors report, “For some gene families the effective topological dimension was on the order of one; in just a few families it was larger than 10.”

“That [the] starting point is the main evolutionary limit is not necessarily surprising, but the scale of its importance is really quite remarkable,” said lead author Lada Isakova, a PhD student within the unit. “As an evolutionary biologist, I was intrigued to see how little selection and epistasis seemed to matter in our results.”

The findings also feed into long‑standing debates about how the first proteins emerged. The team’s simulations suggest that early protein families could not have arisen simply by mutating a single first sequence. Instead, the data point toward DNA recombination “to create new DNA molecules which could encode very different proteins,” explained Isakova.

For today’s protein engineers, the work underscores a practical limitation: AI models trained on existing proteins may struggle to extrapolate into unexplored regions of sequence space. “Most methods won’t be able to generalize well beyond the current known sequence space,” Isakova noted. “We can see there are huge swaths of sequence space left to be explored, but it’ll take new experimental data to enable expansion into these unknown realms.”

The post Common Ancestry Limits Protein Sequence Exploration, Computational Study Shows appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins

Published

on

You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.

The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo-EM images of two proteins, apoferritin and hemoglobin, taken without and with a laser phase plate. The images are analyzed in a computer to produce detailed 3D structures of the proteins. [Holger Müller, Jessie Zhang/UC Berkeley]

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”

The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”

Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

phase plate cover Cryo-EM
A laser (purple) is powerfully amplified by highly polished mirrors and focused on the electron beam (blue) to shift its phase and increase the cryo-EM microscope’s contrast, allowing biologists to image smaller proteins and the crowded structures inside cells. [Sayo Studio]

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.

 

The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”

Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.

“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”

“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”

The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Published

on

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Continue Reading
Advertisement

Trending